262 related articles for article (PubMed ID: 31104335)
1. Integrated analysis of genomics, longitudinal metabolomics, and Alzheimer's risk factors among 1,111 cohort participants.
Darst BF; Lu Q; Johnson SC; Engelman CD
Genet Epidemiol; 2019 Sep; 43(6):657-674. PubMed ID: 31104335
[TBL] [Abstract][Full Text] [Related]
2. Identification of blood metabolites associated with risk of Alzheimer's disease by integrating genomics and metabolomics data.
Liu S; Zhong H; Zhu J; Wu L
Mol Psychiatry; 2024 Apr; 29(4):1153-1162. PubMed ID: 38216726
[TBL] [Abstract][Full Text] [Related]
3. High-resolution metabolomic profiling of Alzheimer's disease in plasma.
Niedzwiecki MM; Walker DI; Howell JC; Watts KD; Jones DP; Miller GW; Hu WT
Ann Clin Transl Neurol; 2020 Jan; 7(1):36-45. PubMed ID: 31828981
[TBL] [Abstract][Full Text] [Related]
4. Integrated network pharmacology analysis and serum metabolomics to reveal the cognitive improvement effect of Bushen Tiansui formula on Alzheimer's disease.
Zhang Z; Yi P; Yang J; Huang J; Xu P; Hu M; Zhang C; Wang B; Peng W
J Ethnopharmacol; 2020 Mar; 249():112371. PubMed ID: 31683034
[TBL] [Abstract][Full Text] [Related]
5. Brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis.
Huo Z; Yu L; Yang J; Zhu Y; Bennett DA; Zhao J
Neurobiol Aging; 2020 Feb; 86():123-133. PubMed ID: 31785839
[TBL] [Abstract][Full Text] [Related]
6. Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease.
Patra K; Soosaipillai A; Sando SB; Lauridsen C; Berge G; Møller I; Grøntvedt GR; Bråthen G; Begcevic I; Moussaud S; Minthon L; Hansson O; Diamandis EP; White LR; Nielsen HM
Alzheimers Res Ther; 2018 Jan; 10(1):9. PubMed ID: 29378650
[TBL] [Abstract][Full Text] [Related]
7. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
[TBL] [Abstract][Full Text] [Related]
9. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
[TBL] [Abstract][Full Text] [Related]
10. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
11. Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults.
Hoscheidt SM; Starks EJ; Oh JM; Zetterberg H; Blennow K; Krause RA; Gleason CE; Puglielli L; Atwood CS; Carlsson CM; Asthana S; Johnson SC; Bendlin BB
J Alzheimers Dis; 2016 Apr; 52(4):1373-83. PubMed ID: 27079723
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of multiple metabolic networks related to brain transmethylation and polyamine pathways in Alzheimer disease: A targeted metabolomic and transcriptomic study.
Mahajan UV; Varma VR; Griswold ME; Blackshear CT; An Y; Oommen AM; Varma S; Troncoso JC; Pletnikova O; O'Brien R; Hohman TJ; Legido-Quigley C; Thambisetty M
PLoS Med; 2020 Jan; 17(1):e1003012. PubMed ID: 31978055
[TBL] [Abstract][Full Text] [Related]
13. One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond.
Dayon L; Guiraud SP; Corthésy J; Da Silva L; Migliavacca E; Tautvydaitė D; Oikonomidi A; Moullet B; Henry H; Métairon S; Marquis J; Descombes P; Collino S; Martin FJ; Montoliu I; Kussmann M; Wojcik J; Bowman GL; Popp J
Alzheimers Res Ther; 2017 Jun; 9(1):43. PubMed ID: 28623948
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage.
Bettcher BM; Johnson SC; Fitch R; Casaletto KB; Heffernan KS; Asthana S; Zetterberg H; Blennow K; Carlsson CM; Neuhaus J; Bendlin BB; Kramer JH
J Alzheimers Dis; 2018; 62(1):385-397. PubMed ID: 29439331
[TBL] [Abstract][Full Text] [Related]
15. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
[TBL] [Abstract][Full Text] [Related]
16. Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease.
Horgusluoglu E; Neff R; Song WM; Wang M; Wang Q; Arnold M; Krumsiek J; Galindo-Prieto B; Ming C; Nho K; Kastenmüller G; Han X; Baillie R; Zeng Q; Andrews S; Cheng H; Hao K; Goate A; Bennett DA; Saykin AJ; Kaddurah-Daouk R; Zhang B; ;
Alzheimers Dement; 2022 Jun; 18(6):1260-1278. PubMed ID: 34757660
[TBL] [Abstract][Full Text] [Related]
17. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
19. Systemic and central nervous system metabolic alterations in Alzheimer's disease.
van der Velpen V; Teav T; Gallart-Ayala H; Mehl F; Konz I; Clark C; Oikonomidi A; Peyratout G; Henry H; Delorenzi M; Ivanisevic J; Popp J
Alzheimers Res Ther; 2019 Nov; 11(1):93. PubMed ID: 31779690
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
